Tocilizumab biosimilar(Hetero Biopharma)

托珠单抗生物类似药（Hetero Biopharma）

Report date: 2025/01/16 15:10:39

Base Information

Drug NameTocilizumab biosimilar(Hetero Biopharma)

Drug Alias NameTocira

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists

TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeN/A